Laurus Labs Limited (LAURUSLABS)
Please see enclosed annexure
AI summary
- Q1 FY27 revenue ₹2,026 Cr, +29% y-y driven by strong CDMO growth and Affordable Medicines
- EBITDA ₹644 Cr, margin 31.8%, +7.0% pts y-y from product mix and operational leverage
- Net profit ₹368 Cr, +126% y-y; EPS ₹6.8, +127% y-y
- CDMO revenue +67% y-y, small molecules +69%, bio +21%
- Affordable Medicines revenue +10% y-y, steady ARV and US launches
- Capex ₹394 Cr (19% of sales) for manufacturing expansion and niche capabilities
- Advanced Biologics R&D spend up 74%, focus on gene therapy and ADC
- Healthy order book with 125+ active projects and capacity expansions ongoing
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 LAURUSLABS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add LAURUSLABS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Laurus Labs Limited
Important.
The summary above is generated automatically from Laurus Labs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.